Skip to main content
DBD
NYSE Technology

Diebold Nixdorf Q2 2026: Revenue Climbs 1.7% as Retail Surges 24%, $115M in Buybacks

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Software Stocks · Technology
Sentiment info
Neutral
Importance info
7
Price
$75.17
Mkt Cap
$2.603B
52W Low
$53.93
52W High
$92.085
52W Position info
39% above low
Off High info
18% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

DBD sits 39% above its 52-week low of $53.93 on elevated volume (2.1× avg).

Summary

Diebold Nixdorf reported Q2 2026 revenue of $930.8M, up 1.7% YoY, with Retail surging 24% while Banking declined 6.1%. The company repurchased $115M in shares during H1, boosting EPS to $0.44 diluted.


Key Events · Earnings and Guidance · DBD

  • Revenue Up 1.7%, Retail Surges

    Q2 2026 revenue reached $930.8M, a 1.7% increase YoY. A 24% jump in Retail revenue to $292.7M, driven by strong electronic point-of-sale business, more than compensated for a 6.1% decline in Banking revenue to $638.1M, which suffered from lower product volumes.

  • Earnings Per Share Rises

    Diluted EPS climbed to $0.44 from $0.33 in Q2 2025. Net income attributable to Diebold Nixdorf was $15.5M, compared to $12.2M a year ago, aided by lower foreign exchange losses and a reduced share count from buybacks.

  • Aggressive Share Repurchases

    The company repurchased 1.5 million shares for $115M in H1 2026, reducing the outstanding share count to 34.0 million. Under the $200M buyback program authorized in November 2025, $57M remains available.

  • Restructuring Charges Continue

    Restructuring charges totaled $43.7M in H1 2026, primarily tied to the Operational Evolution Program aimed at improving efficiency. The program is expected to cost $105M in total, with $70.6M recognized to date.


Analysis · DBD · Technology

Diebold Nixdorf's Q2 results present a mixed picture. Total revenue grew 1.7% to $930.8M, fueled by a 24% surge in Retail that offset a 6.1% decline in Banking. Gross margin edged up to 25.7%, yet operating profit was nearly flat. Net income attributable to Diebold Nixdorf rose to $15.5M from $12.2M, helped by lower foreign exchange losses. Aggressive share repurchases of $115M during H1 reduced the share count and boosted EPS. Meanwhile, restructuring charges of $43.7M reflect ongoing efficiency efforts, and the effective tax rate jumped to 51.3%, pressuring net income. Cash from operations fell to $18.1M from $45.8M, partly due to an inventory build. The balance sheet remains solid with $282.4M in cash and no borrowings on the $310M revolver.

At the time of this filing, DBD was trading at $75.17 on NYSE in the Technology sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $53.93 to $92.09. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DBD - Latest Insights

DBD
Jul 29, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $90.75
Real-time Price: $75.17 info
Change: -$15.58 (-17%) info
Market Cap: $2.603B info
DBD
Jun 26, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $84.98
Real-time Price: $75.17 info
Change: -$9.81 (-12%) info
Market Cap: $2.603B info
DBD
Apr 30, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $82.50
Real-time Price: $75.17 info
Change: -$7.33 (-9%) info
Market Cap: $2.603B info
DBD
Apr 17, 2026, 4:28 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $88.60
Real-time Price: $75.17 info
Change: -$13.43 (-15%) info
Market Cap: $2.603B info
DBD
Apr 10, 2026, 4:04 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $84.78
Real-time Price: $75.17 info
Change: -$9.61 (-11%) info
Market Cap: $2.603B info